Stryker (SYK) is back in focus after its Stryker Sales unit secured a $100 million contract modification from the US Defense Logistics Agency, a development that coincided with a 2.7% share price move. See our latest analysis for Stryker. For context, Stryker’s share price has been volatile around recent news, with a 4.17% 1 month share price return and a 5.88% decline year to date, while the 1 year total shareholder return is down 13.98%, the 3 year total shareholder return is up 23.40%, and...

Check out the companies making headlines yesterday:

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

Despite its disappointing performance relative to the broader market over the past year, Stryker continues to enjoy strong backing from Wall Street.

Shares of medical technology company Stryker (NYSE:SYK) jumped 2.7% in the afternoon session after its Stryker Sales unit in Michigan won a $100 million contract modification from the US Defense Logistics Agency.

Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.

Mercury Systems (NASDAQ:MRCY) reported record fourth-quarter bookings, backlog and revenue for fiscal 2026, as the defense technology company cited broad demand across its portfolio and raised its long-term organic-growth target. Chairman and Chief Executive Officer Bill Ballhaus said fourth-quarte

ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.

Stryker (NYSE:SYK) reported strong first quarter growth, supported by underlying demand and a recovery from a prior cyber incident. The company highlighted organic growth across its main divisions that was driven by customer volume rather than acquisitions. A wide gap between reported and adjusted earnings raised questions about ongoing costs that are weighing on profitability. For readers interested in other income focused healthcare ideas, the next logical step is to explore 11 dividend...

Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Stryker's medical...

Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.

Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.

Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.